Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sarclisa, multiple myeloma and European Medicines Agency
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade, plus Revlimid, plus dexamethasone (VRd) for treating newly diagnosed multiple myeloma (MM).
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ
Sanofi: Sarclisa Recommended for EU Approval by CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
2d
on MSN
Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stages
Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Medpage Today on MSN
1d
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer
GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in ...
clinicaltrialsarena on MSN
20h
GSK reports positive outcomes from Phase III multiple myeloma treatment trial
GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
Targeted Oncology
12h
Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
News Medical on MSN
1d
Interactive atlas unveils immune changes in multiple myeloma
Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
Military.com
3d
VA Set to Add Leukemia, Multiple Myeloma to List of Conditions Linked to Burn Pits
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
Targeted Oncology
8h
Usmani Projects a Future of CAR T in Community for Myeloma and Other Cancers
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
BioSpace
1d
GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
The American Journal of Managed Care
9h
Elevating Myeloma Care Amidst Complex Treatment Choices
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
Healthcare Asia on MSN
1d
Pharmaceutical firms eye multiple myeloma amidst rising incidence rates
The increase has been faster in women since 2000. The rising incidence of multiple myeloma (MM), particularly in relapsed and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Blenrep
Sarclisa
Sanofi
GSK
GlaxoSmithKline
Feedback